01-26-2021, 09:03 PM
The title is "Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant"
For the rest of us, "host-directed" means, if I understand it correctly, that the therapy makes changes in the host (the person with COVID) that results in efficacy against the virus. The idea is that the virus is less likely to evolve to avoid the therapy. So, the title means that therapies developed against virus from back in the first part of 2020 are still effective against the recent B.1.1.7.
For the rest of us, "host-directed" means, if I understand it correctly, that the therapy makes changes in the host (the person with COVID) that results in efficacy against the virus. The idea is that the virus is less likely to evolve to avoid the therapy. So, the title means that therapies developed against virus from back in the first part of 2020 are still effective against the recent B.1.1.7.